新型机械二尖瓣的中期生存、临床与血流动力学结局
基于PROACT随机试验5年结果,评估On-X机械二尖瓣的中期生存、临床与血流动力学结局。401例二尖瓣置换患者(Standard或Conform-X瓣环,比较低剂量与标准剂量华法林)的汇总分析显示,5年生存率92.4%,平均跨瓣压差稳定在4.6±2.0 mm Hg,96.6%患者心功能为NYHA I或II级。
要点
- On-X机械二尖瓣5年生存率92.4%,Standard与Conform-X瓣环间无显著差异。
- 1年平均跨瓣压差4.6±2.0 mm Hg,随时间稳定,瓣膜大小与体表面积无交互作用。
- 最新随访96.6%患者为NYHA I或II级,生活质量改善。
核心结论
- On-X机械二尖瓣植入后5年内显示良好的生存率、稳定的血流动力学和改善的生活质量。
研究设计与样本
- PROACT Mitral为多中心研究,纳入401例接受二尖瓣置换的患者,使用Standard或Conform-X On-X机械二尖瓣,比较低剂量与标准剂量华法林。
- 本文报告预设次要结局:汇总人群1、3、5年的生存率、NYHA功能分级和核心实验室判定的超声心动图瓣膜血流动力学。
主要发现
- 1年、3年、5年 actuarial 生存率分别为99.7%、95.1%、92.4%,Standard与Conform-X瓣环间无显著差异。
- 1年平均跨瓣压差为4.6±2.0 mm Hg,瓣膜大小与患者体表面积无交互作用,跨瓣压差随时间保持一致。
- 最新可随访(3年或5年)时96.6%患者为NYHA I或II级。
- 不同瓣膜大小间生存、临床或血流动力学结局无显著差异。
临床怎么用
- 这些来自高质量随机试验的数据可指导需要二尖瓣置换的年轻患者的决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the midterm survival, clinical, and hemodynamic outcomes of the On-X mechanical mitral valve, based on the 5-year results of the Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT). METHOD: PROACT Mitral was a multicenter study evaluating 401 patients who underwent mitral valve replacement (MVR) with either Standard or Conform-X On-X mitral valves, comparing low-dose and standard-dose warfarin. Here we report prespecified secondary outcomes of survival, New York Heart Association (NYHA) functional classification, and valve hemodynamics as assessed by core lab-adjudicated echocardiography at 1, 3, and 5 years in the pooled population. RESULTS: Actuarial survival was 99.7% at 1 year, 95.1% at 3 years, and 92.4% at 5 years, with no significant difference between the Standard and Conform-X cuffs. Hemodynamic analysis revealed a mean transvalvular pressure gradient (MG) of 4.6 ± 2.0 mm Hg at 1 year, with no interaction between valve size and patient body surface area. MG values were consistent over time. Quality of life improved with 96.6% of patients in NYHA class I or II at the latest available follow-up of 3 or 5 years. There were no significant differences in survival, clinical, or hemodynamic outcomes between valve sizes. CONCLUSIONS: The On-X mechanical mitral valve demonstrated favorable survival, stable hemodynamics, and enhanced quality of life up to 5 years postimplantation. Derived from high-quality, rigorous randomized trial data, these findings can guide decision making in young patients requiring MVR.
引用
- Ruel M, Chu MWA, Graeve A, et al. Midterm survival, clinical, and hemodynamic outcomes of a novel mechanical mitral valve prosthesis. J Thorac Cardiovasc Surg. 2024. PMID: 39617318. doi:10.1016/j.jtcvs.2024.11.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。